Black Diamond Financial’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Black Diamond Financial’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-71,000	Closed	-$415K	–	120
2022 Q4	$415K	Hold	71,000	–	–	0.15%	67
2022 Q3	$476K	Buy	71,000 +2,000	+3%	+$12.1K	0.19%	62
2022 Q2	$290K	Buy	69,000 +23,000	+50%	+$91K	0.11%	86
2022 Q1	$155K	Hold	46,000	–	–	0.05%	122
2021 Q4	$145K	Hold	46,000	–	–	0.05%	93
2021 Q3	$150K	Buy	46,000 +11,500	+33%	+$40.3K	0.07%	75
2021 Q2	$146K	Buy	+34,500	New	+$146K	0.06%	84

Black Diamond Financial's CNCE Position: Q1 2023 in Review

Black Diamond Financial sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 71,000 shares — an estimated $415K sold.

Black Diamond Financial first reported a position in CNCE in Q2 2021 and held it in 7 quarters. The position peaked at $476K in Q3 2022. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.

Black Diamond Financial reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
Black Diamond Financial sold 71,000 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $415K.
Black Diamond Financial first reported a position in Concert Pharmaceuticals, Inc. in Q2 2021 and held it in 7 quarters.
Black Diamond Financial's Concert Pharmaceuticals, Inc. position peaked at $476K in Q3 2022.
0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.

Based on Black Diamond Financial's 13F filing for Q1 2023, filed 11 May 2023.